Skip Navigation

ACS is committed to helping combat the global COVID-19 pandemic with initiatives and free resources. Learn More

Jonathan Mason

Jonathan Mason

Dr. Jonathan Mason is a Senior Research Fellow at Heptares Therapeutics in the UK leading Computer-Assisted Drug Design (CADD) approaches for GPCR structure-based drug design, scientifically responsible for the computational chemistry team.  A ‘high end’ GPCR design approach combining structure, water energetics, lipophilic hotspots and biophysical data is being developed. He has 35 years of global pharmaceutical drug discovery experience and is an experienced leader and scientific expert for drug design technologies (computational medicinal chemistry / CADD, structural biology, in silico ADME/tox etc). He previously led teams involving computational and lead discovery chemistry at Lundbeck in Copenhagen (Divisional Director), computational chemistry, structural biology, medicinal informatics and knowledge discovery at Pfizer in the UK (Executive Director MISD) and Bristol-Myers Squibb in the US (Director SB&M). Prior to these Jon was at Rhône-Poulenc Rorer (now Sanofi) in the UK, France and US, building and leading CADD teams. Jon started his career as a synthetic medicinal chemist (PhD, Queen Mary, University of London), 5 years later becoming an early pioneer of the use of computational approaches in discovery research, particularly the development and use of 3D pharmacophore fingerprint methods for both protein structure-based drug design (SBDD) and ligand-based similarity/diversity approaches. More recent focus includes the use of biological fingerprints to tackle attrition-related problems including lead selection / differentiation, fragment-based drug discovery and bringing full binding site water networks and their energetics into routine drug design as an essential component to enable more effective ligand design for GPCR and enzyme targets and new perspectives for druggability.